NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Liver Cyst


Return to Library

Free Liver Cyst Articles


New echinococcosis research from Cumhuriyet University, Medical Department outlined



2009 JUN 29 - (NewsRx.com) -- "Dissemination of protoscolices-rich fluid during surgery for hydatid cyst disease is a major cause of recurrence. Instillation of a scolicidal agent into a hepatic hydatid cyst before opening is the most commonly employed measure to prevent this serious complication," scientists in Sivas, Turkey report.

"In this clinical study, the efficacy of 0.04% chlorhexidine gluconate (Chx-Glu) during hydatid cyst surgery was tested, and early-term results were evaluated. A total of 30 consecutive patients with 45 liver cysts were studied. Only type I and type II cysts were included. Cysts were punctured, and fluid was aspirated. The viability of protoscolices in this fluid was determined. Chx-Glu 0.04% was instilled into the cyst cavity. After 5 minutes of exposure, the cyst fluid was reaspirated and evaluated for the viability of protoscolices. Imprints of the germinative membranes were determined for protoscolices viability. All protoscolices in 45 cysts evaluated were killed by 5 minutes of exposure to 0.04% Chx-Glu. The whole of the germinative membrane imprints contained dead protoscolices. Chx-Glu 0.04% did not cause any adverse effect on biliary tracts in communication with cysts. There was no recurrence during the 2-year follow-up period. There were also no mortality and no cavity-related complications. This study shows that intracystic injection of 0.04% Chx-Glu is an effective measure against the dissemination of viable protoscolices. In addition, Chx-Glu is the most convenient scolicidal agent as per the criteria defined by the World Health Organization. Therefore, it can be used safely during hydatid cyst surgery," wrote O. Topcu and colleagues, Cumhuriyet University, Medical Department.

The researchers concluded: "However, there remains the need to perform advanced comparative clinical studies on the efficacy of Chx-Glu and other scolicidal agents."

Topcu and colleagues published their study in World Journal of Surgery (Efficacy of Chlorhexidine Gluconate During Surgery for Hydatid Cyst. World Journal of Surgery, 2009;33(6):1274-1280).

For more information, contact O. Topcu, Cumhuriyet University, Faculty Medical, Dept. of General Surgery, TR-58140 Sivas, Turkey.

Publisher contact information for the World Journal of Surgery is: Springer, 233 Spring St., New York, NY 10013, USA.

Keywords: Turkey, Sivas, Antibiotic, Antiinfective, Chlorhexidine Gluconate, Clinical Trial Research, Cysts, Drugs, Echinococcosis, Gastroenterology, Hepatology, Liver Cyst, Pharmaceuticals, Surgery, Therapy, Treatment, Cumhuriyet University, Medical Department.

This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.

NewsRx NewsRx NewsRx
-----------------------
PR Login